Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis

Completed

Conditions: Liver Metastases
Colorectal Cancer

Interventions: Procedure: Repeat Liver Surgery
Procedure: Non-Repeat Liver Surgery

First Posted Date: 2022-07-18

Last Posted Date: 2022-07-19

Lead Sponsor: Fudan University

Target Recruit Count: 255

Registration Number: NCT05462470

Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP

Phase 2

Recruiting

Conditions: Endometrial Cancer

Interventions: Drug: Letrozole 2.5mg

First Posted Date: 2022-07-12

Last Posted Date: 2023-09-13

Lead Sponsor: Fudan University

Target Recruit Count: 299

Registration Number: NCT05454358

Locations: 🇨🇳
Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China

Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy

Phase 2

Not yet recruiting

Conditions: Colorectal Cancer Stage IV
Colorectal Cancer

Interventions: Drug: Capecitabine
Drug: Fruquintinib Plus Capecitabine

First Posted Date: 2022-07-11

Last Posted Date: 2022-07-12

Lead Sponsor: Fudan University

Target Recruit Count: 116

Registration Number: NCT05451719

Bespoke ctDNA Assay for Recurrence and Treatment Response Monitoring in Advanced Epithelial Ovarian Cancer

Recruiting

Conditions: Ovarian Cancer

Interventions: Other: ND-EOC or platinum-sensitive rEOC

First Posted Date: 2022-07-06

Last Posted Date: 2023-12-28

Lead Sponsor: Fudan University

Target Recruit Count: 139

Registration Number: NCT05446545

Locations: 🇨🇳
Hao Wen, Shanghai, Shanghai, China

Value of Pleural Lavage Cytology in Resectable Esophageal Carcinoma Eastern Cooperative Thoracic Oncology Projects 2005, ECTOP-2005)

Recruiting

Conditions: Esophageal Cancer

First Posted Date: 2022-07-05

Last Posted Date: 2023-07-13

Lead Sponsor: Fudan University

Target Recruit Count: 385

Registration Number: NCT05443841

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijia Zhuang, Hebei, China
🇨🇳
The First Affiliated Hospital of USTC, Hefei, Anhui, China
🇨🇳
Henan Provincial People's Hospital, Zhengzhou, Henan, China

and more 8 locations

Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Phase 2

Recruiting

Conditions: Hepatopathy

Interventions: Drug: Placebo
Drug: Hetrombopag

First Posted Date: 2022-07-05

Last Posted Date: 2024-03-13

Lead Sponsor: Fudan University

Target Recruit Count: 96

Registration Number: NCT05442632

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Social Media-based Vaccine Confidence and Hesitancy Monitoring

Withdrawn

Conditions: Vaccination Refusal
Information Dissemination
Machine Learning
Internet-Based Intervention
Social Medium
Patient Acceptance of Health Care
Data Collection
Immunization Programs

First Posted Date: 2022-07-05

Last Posted Date: 2022-07-05

Lead Sponsor: Fudan University

Registration Number: NCT05442762

A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: chidamide
Drug: camrelizumab
Drug: capecitabine
Drug: carboplatin

First Posted Date: 2022-06-30

Last Posted Date: 2022-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 70

Registration Number: NCT05438706

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy

Phase 2

Active, not recruiting

Conditions: Colorectal Cancer

Interventions: Procedure: HAIC
Drug: Fruquintinib
Drug: Tislelizumab
Drug: Raltitrexed
Drug: Oxaliplatin
Drug: Irinotecan

First Posted Date: 2022-06-28

Last Posted Date: 2024-01-17

Lead Sponsor: Fudan University

Target Recruit Count: 39

Registration Number: NCT05435313

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

ctDNA-based MRD Assessment in Local Advanced Esophageal Carcinoma

Recruiting

Conditions: Esophageal Squamous Cell Carcinoma

First Posted Date: 2022-06-22

Last Posted Date: 2022-06-22

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT05426850

Locations: 🇨🇳
Fudan University Shanghai cancer center, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy